Business Context and Reporting Period
Company: Autolus Therapeutics Plc (Autolus)
Filing Type: Form 10-Q (Voluntary filing by Foreign Private Issuer)
Reporting Period: Three months ended March 31, 2026
Business Overview: Autolus is a commercial-stage biopharmaceutical company developing programmed T cell therapies. Its primary commercial product is AUCATZYL (obecabtagene autoleucel), approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). The product launched in the U.S. in January 2025 and the U.K. in January 2026. EU launch remains on hold.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Product Revenue, Net | $26,218 | $8,982 |
| Cost of Sales | $(24,568) | $(17,951) |
| Gross Profit | $1,650 | $(8,969) |
| Research & Development Expenses | $(21,210) | $(26,734) |
| Selling, General & Administrative Expenses | $(39,953) | $(29,537) |
| Net Loss | $(71,598) | $(70,161) |
| Net Loss Per Share (Basic & Diluted) | $(0.27) | $(0.26) |
| Cash, Cash Equivalents & Restricted Cash | $132,418 | $97,251 |
| Marketable Securities | $98,509 | $196,578 |
| Total Liabilities | $418,239 | $410,939 |
| Accumulated Deficit | $(1,458,350) | $(1,386,752) |
Liquidity: As of March 31, 2026, the company held $130.9 million in cash and cash equivalents and $98.5 million in marketable securities. Management believes these resources are sufficient to fund operations for at least 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Net product revenue increased 192% to $26.2 million, driven by increased doses administered in the U.S. and the new U.K. launch in January 2026.
- Cost of Sales: Increased 37% to $24.6 million due to higher raw material consumption and manufacturing support costs. Gross margin improved from negative to positive ($1.65M) due to the utilization of "zero cost" inventory (materials previously expensed as R&D).
- Operating Expenses:
- R&D: Decreased 21% to $21.2 million, primarily due to lower clinical trial costs and reduced U.K. R&D tax credits (transition from SME to RDEC scheme).
- SG&A: Increased 35% to $39.9 million, driven by higher personnel costs for commercialization and professional fees.
- Foreign Exchange: Shifted from a $1.2 million gain in Q1 2025 to a $2.7 million loss in Q1 2026 due to currency fluctuations on monetary assets and liabilities.
- Interest Expense: Increased 10% to $11.1 million, reflecting higher accrued interest on liabilities related to future royalties and milestones (Blackstone and BioNTech agreements).
Outlook, Risks, and Unusual Items
- Restructuring: In April 2026, the company announced a reduction in force affecting approximately 13% of its workforce. Total estimated costs are $8 million, with a significant portion expected to be recognized in the first half of 2026. This is expected to reduce annualized operating expenses by ~$15 million starting in 2027.
- EU Launch Status: While marketing authorization was granted in July 2025, the commercial launch in the EU (including Germany) is currently on hold pending pricing and feasibility evaluations. No EU revenue is anticipated in 2026.
- Collaboration Liabilities: Significant non-cash interest expense is driven by the Blackstone Collaboration Agreement and BioNTech License and Option Agreement. The carrying amount of these liabilities was $289.2 million as of March 31, 2026.
- Tax Credit Uncertainty: The company is in ongoing discussions with the U.K. tax authority regarding an R&D tax credit claim for the period ended December 2023. A resolution could result in a material gain or reduction in the receivable.
- Pipeline Updates:
- Obe-cel (LN): Pivotal LUMINA Phase 2 trial enrolling; data expected in 2028.
- Obe-cel (MS): Phase 1 BOBCAT trial enrolling; initial data expected end of 2026.
- AUTO8: First patient dosed in ALARIC trial for AL-Amyloidosis; data expected end of 2026.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of AUCATZYL sales in the U.S. and U.K. to ensure the 192% growth is sustainable and not a one-time spike.
- Restructuring Execution: Monitor the timing and magnitude of the $8 million restructuring charges and the actual realization of the projected $15 million annualized savings.
- EU Market Entry: Track the status of pricing negotiations and launch feasibility in the EU, as this represents a significant potential revenue stream currently on hold.
- Cash Burn Rate: Assess the net cash used in operating activities ($65.3M for Q1) against the current cash balance ($229.4M total liquid assets) to confirm the 12-month runway.
- Tax Credit Resolution: Monitor the outcome of the U.K. tax authority discussions regarding the R&D intensive scheme claim, which impacts the $17.0 million receivable.